Handelsbanken Fonder AB Has $29.05 Million Stock Position in IQVIA Holdings Inc. $IQV

Handelsbanken Fonder AB cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 184,316 shares of the medical research company’s stock after selling 3,893 shares during the period. Handelsbanken Fonder AB owned about 0.11% of IQVIA worth $29,046,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Clal Insurance Enterprises Holdings Ltd increased its stake in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the last quarter. Trust Co. of Toledo NA OH bought a new position in shares of IQVIA in the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp increased its position in shares of IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 169 shares during the last quarter. Rothschild Investment LLC increased its position in shares of IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the last quarter. Finally, NewSquare Capital LLC raised its holdings in IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after acquiring an additional 189 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Citigroup boosted their price target on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 29th. TD Cowen cut shares of IQVIA from a “buy” rating to a “hold” rating and raised their target price for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Finally, Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $240.61.

IQVIA Trading Up 3.7%

Shares of IQVIA stock opened at $225.09 on Friday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $228.12. The company has a market capitalization of $38.33 billion, a price-to-earnings ratio of 30.88, a P/E/G ratio of 2.43 and a beta of 1.34. The business has a fifty day simple moving average of $205.80 and a two-hundred day simple moving average of $180.82. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.